(Q43174432)

15 November 2017

title

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors (English)

1 reference

15 November 2017

2

1 reference

15 November 2017

8

1 reference

15 November 2017

12

1 reference

15 November 2017

13

T P Hughes

1 reference

15 November 2017

D K Hiwase

1

1 reference

15 November 2017

J A Powell

3

1 reference

15 November 2017

V A Saunders

4

1 reference

15 November 2017

S A Zrim

5

1 reference

15 November 2017

A K Frede

6

1 reference

15 November 2017

M A Guthridge

7

1 reference

15 November 2017

R J D'Andrea

9

1 reference

15 November 2017

L B To

10

1 reference

15 November 2017

J V Melo

11

1 reference

15 November 2017

publication date

4 February 2010

1 reference

15 November 2017

1 reference

15 November 2017

volume

24

1 reference

15 November 2017

issue

4

1 reference

15 November 2017

page(s)

771-778

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.299

15 November 2017

exact match

0 references

cites work

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

inferred from DOI database lookup

7 January 2021

based on heuristic

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.299

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2009.299

1 reference

Dimensions Publication ID

15 November 2017

1030908591

0 references

1 reference